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The impact of HIV-1 expression in the brain on the development of AIDS is unknown. In the present study, we examined
the hypothalamic-pituitary-adrenal (HPA) axis in a transgenic model in which expression of the HIV-1 envelope glycoprotein
gp120 induced central nervous system (CNS) damage similar to that seen in HIV-1-infected patients. Compared with
nontransgenic littermates, gp120 transgenic mice showed significant increases in plasma corticosterone and adrenocortico-
trophic hormone (ACTH) levels and pituitary ACTH content. To determine whether this activation of the HPA axis could be
mediated by ACTH secretagogues, the effect of recombinant gp120 on the release of these factors from hypothalamic
slices was investigated in vitro. Recombinant gp120 induced release of the ACTH secretagogue arginine vasopressin from
nontransgenic hypothalamic slices in a calcium-dependent fashion. This effect was inhibited by antagonists of N-methyl-D-
aspartate (NMDA) receptors or of nitric oxide synthase (NOS), suggesting a role for NMDA receptor stimulation and NOS
activity. Further evidence for a role of free radicals was obtained from bigenic mice coexpressing gp120 and the free radical
scavenger human copper/zinc superoxide dismutase which showed normal corticosterone levels. This might relate to
superoxide dismutase-mediated scavenging of superoxides generated by NOS. These findings demonstrate that CNS expres-
sion of a viral envelope protein can activate the HPA axis and thereby alter peripheral levels of immunomodulatory hormones.
q 1996 Academic Press, Inc.
The central nervous system (CNS) controls many func- The expression of fusion genes in transgenic animals
tions of the body including those of the immune system allows for the intraparenchymal production of specific
(Reichlin, 1993). Since CNS alterations are frequently en- proteins and, hence, can help in the assessment of a
countered in HIV-1-infected individuals (Price and Perry, molecule’s relative pathogenetic importance, in the iden-
1994), disturbances of regulatory CNS-immune interac- tification of pathogenetic mechanisms, and in the devel-
tions could play a role in AIDS pathogenesis. It is there- opment and evaluation of therapeutic strategies aimed
fore interesting that several studies have reported in- at amelioration of damage (for review see Toggas and
creased plasma cortisol levels in humans with HIV-1 in- Mucke, 1996). Recently, we established a transgenic
fection (for review see Refaeli et al., 1995). However, the model in which glial expression of a fusion gene encod-
exact cause of this hormonal alteration is unknown. ing the soluble, secretable HIV-1 envelope protein gp120
In general, elevated plasma glucocorticoid levels may results in CNS abnormalities that in many respects re-
result from a primary overproduction by the adrenal gland semble neuropathological alterations found in patients
or from central alterations in the hypothalamus/pituitary with AIDS (Toggas et al., 1994). These abnormalities in-
which induce an overproduction of adrenocorticotrophic clude drop-out of presynaptic terminals and neuronal
hormone (ACTH), the main hormone upmodulating gluco- subpopulations, vacuolar degeneration of neuronal den-
corticoid production. Unfortunately, HIV-infected patients drites as well as microgliosis and astrocytosis. In the
exhibit so many complex interactions among microbial current study we demonstrate that gp120 transgenic
and host-derived factors that it is difficult to determine mice possess elevated plasma corticosterone and adre-
whether the expression of viral products is sufficient to nocorticotrophic hormone (ACTH) levels. Since HIV-in-
induce such alterations. duced hypothalamic-pituitary-adrenal (HPA) axis activa-
tion could be mediated by the ACTH secretagogues argi-
nine vasopressin (AVP) and/or corticotropin releasing1 To whom correspondence should be addressed at present address:
Gladstone Molecular Neurobiology Program and Department of Neurol- factor (CRF), we also studied the effects of gp120 on
ogy, University of California, San Francisco, CA 94141-9100. Fax: (415) the hypothalamic release of these factors. Exposure of
26- 6541.
nontransgenic hypothalamic slices to recombinant gp1202 Present address: Gladstone Molecular Neurobiology Program and
resulted in the release of AVP. These findings suggestDepartment of Neurology, University of California, San Francisco, CA
94141-9100. that expression of HIV-1 gp120 within the CNS can alter
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the functioning of the HPA axis and result in the elevation mice were placed in a restrainer for 15 min, anesthetized,
and tail bled.of hormones that have the potential to affect the immune
system as well as the CNS. Plasma corticosterone was determined using a corti-
costerone kit for rats and mice from ICN Biomedicals
(Costa Mesa, CA). The intra- and interassay coefficients
MATERIALS AND METHODS
of variation were both 7%. Plasma ACTH was determined
using a kit from Nichols Institute (Capistrano, CA). TheAnimals
intra- and interassay coefficients of variation were 3 and
7%, respectively.The generation of gp120 transgenic mice expressing
HIV-1 gp120 from the glial fibrillary acidic protein (GFAP)
Determination of pituitary ACTH contentpromoter has been described previously (Toggas et al.,
1994). Founder mice were obtained from microinjections To measure pituitary ACTH content, mice were anes-
of one cell C57BL/6 1 SJL (B6 1 SJL) embryos. All singly thetized with metofane for 2 min, decapitated, and the
transgenic mice and nontransgenic littermate controls pituitaries dissected out and placed into tubes on dry ice
were generated by crosses between heterozygous until extraction and assay for ACTH. To avoid circadian
transgenic mice (see below) with nontransgenic breed- variation, mice were sacrificed between 10:00 AM and
ers (B6 1 SJL F1 or Balb/cByJ inbreds). The following 12:00 PM (noon). ACTH was extracted from frozen pituitar-
mice were used in the current experiments: GFAP-gp120 ies by adding 500 ml of 2 N acetic acid, boiling for 10
transgenic mice of the high expressor line 2 (original min, cooling on ice, sonicating twice for 3 sec with a
B6 1 SJL hybrid background or predominantly Balb/cByJ Vir Sonic 50 (The Virtus Company, Gardiner, NY), and
derived by third generation backcross onto Balb/cByJ in- centrifugation at 10,000 g for 10 min. From the superna-
breds), and moderate expressor line 10 (B6 1 SJL), tant of each sample, a 10-ml aliquot was taken for deter-
GFAP-TGF-b1 transgenic mice of line 15 (Balb/cByJ) mination of protein concentration and 450 ml were lyophi-
(Wyss-Coray et al., 1995), human copper/zinc superoxide lized overnight (Freeze mobile 5SL, The Virtis Co.). Pro-
dismutase (SOD) transgenic mice derived from line tein concentrations were determined using the Micro
HS218 (C57BL/6) (Epstein et al., 1987), and non- BCA* protein assay reagent kit (Pierce, Rockford, IL).
transgenic littermate controls. Crosses between hetero- The lyophilized samples were resuspended in 450 ml RIA
zygous gp120 singly transgenic mice (B6 1 SJL) and buffer (Raber et al., 1994) and stored at 0707 until the
heterozygous SOD singly transgenic mice (C57BL/6) time of the assay as described above. ACTH levels were
were used to generate gp120/SOD bigenic mice as well corrected for the amount of protein present in each sam-
as (gp120 or SOD) singly transgenic and nontransgenic ple and expressed per milligram of protein.
littermate controls. All mice were housed at no more than
four per cage under conditions of constant temperature Dissection of hypothalami
(187), light during 6:00 AM –6:00 PM, and access to water
Normal nontransgenic Balb/cByJ mice (6 to 11 weeksad libitum.
of age) were sacrificed by decapitation between 10:00
and 11:00 AM (to avoid circadian variation), and their
Collection of plasma samples and hormonal brains were removed rapidly. A brain slicer (San Diego
measurements Instruments, San Diego, CA) was used to obtain a 1.5-
mm-thick slice in the coronal plane, including structuresAnimals were anesthetized with metofane for 2 min 00.7 mm caudal to Bregma, according to Slotnick andand subsequently tail bled using heparinized capillary
Leonard (1975). Subsequently the hypothalamic regiontubes (Baxter, Mc Gaw Park, IL). To avoid circadian varia-
was excised, according to the following anatomicaltion, tail bleeding and euthanasia of mice were carried
boundaries: the region between two vertical cuts at theout between 10:00 AM and 12:00 PM (noon). Blood was
two lateral hypothalamic sulci, and a horizontal cutplaced into Eppendorf tubes which were kept on ice. For
through the mammillothalamic tracts and the rhomboiddeterminations of plasma ACTH, blood from the tail was
thalamic nucleus. The dissected tissue was placed ontocollected using EDTA-coated tubes (Microtainer, Bec-
a Brinkmann tissue chopper (The Mickle Laboratory En-ton–Dickinson, Rutherford, NJ) and kept on ice. Alterna-
gineering Co. LTD, Gomshall, Surrey, England), and 300-tively, for determination of plasma ACTH and corticoste-
mm slices were prepared. Slices from one hypothalamusrone, blood from the body was collected after decapita-
were placed into one superfusion chamber.tion using EDTA-coated tubes. After centrifugation at
10,000 g for 10 min at 47, the supernatants were stored
Incubation system
at 0707 until assay for corticosterone or ACTH. These
were considered baseline values, although metofane an- Tissue slices were incubated in balanced Earle’s salt
solution (Gibco, Grand Island, NY), supplemented withesthesia may induce some stress. To determine the ef-
fect of restraint stress on plasma corticosterone levels, 60 mg/ml ascorbic acid (Fisher) and 0.54 mg/ml glucose
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at 377 under an atmosphere of O2/CO2 (95%/5%) using The lower detection limit of the assay was 3 pg/tube (100
ml sample volume). The intra- and interassay coefficientsan in vitro superfusion system (Scripps Instrument Labo-
ratories, according to a model from Dr. P. P. Magistretti, of variation were 3 and 10%, respectively.
University of Lausanne, Switzerland), containing a multi-
channel peristaltic pump (Watson-Merlow), for a total of Statistics
220 min. The flow rate was 66.7 ml/min. First, the general
All data in this study were expressed as mean { SEM.properties and responsivity of mouse hypothalamic
For comparisons of means, analysis of variance (ANOVA)slices were assessed. Because basal release stabilized
was used, followed by Tukey–Kramer posthoc test whenafter 90 min, a 100-min interval was chosen as the first
appropriate. A probability value of less than 0.05 wasbasal period for all subsequent experiments. The 220-
considered significant.min period was composed of a 100-min preincubation
period (to allow for stabilization of basal release), and
RESULTSa 120-min sample collection period. During the sample
collection period, fractions were collected at 15-min inter- GFAP-gp120 mice possess elevated plasma
vals, placed on dry ice, and stored at 0707C until the corticosterone levels
time of the assay. To ensure tissue viability, data were
discarded from experiments in which there was not a To investigate whether cerebral expression of gp120
in transgenic mice could elicit alterations in the produc-vigorous release (at least 50% over baseline) after addi-
tion of 60 mM KCl at the end of the experiment. To investi- tion of immunomodulatory hormones, we analyzed the
plasma corticosterone levels in these mice by radioim-gate the effect of gp120 on release of AVP or CRF from
the hypothalamus, tissues were incubated between 115 munoassay. Basal corticosterone levels were strongly
increased in 6- and 11-week-old heterozygous trans-and 190 min with recombinant gp120 (HIV-1IIIB baculovi-
rus expressed, Agmed, Bedford, MA) at concentrations genic mice of the Balb/cByJ strain background compared
with nontransgenic littermate controls (Fig. 1A). Heterozy-(10 pM, 3 nM, 10 nM) that had previously been shown
to induce clear neurobiological effects (Dawson et al., gous transgenic mice of the B6 1 SJL hybrid strain
showed elevations of lower magnitude (Fig. 1B). In con-1993; Mollace et al., 1994; Pietraforte et al., 1994; Pitaluga
and Raiteri, 1994). To ensure that the effect of gp120 on trast to 6- to 11-week-old gp120 transgenic mice (Fig. 1),
6-month-old gp120 transgenic mice of both the Balb/cByJAVP release was due specifically to gp120 and not to an
impurity in the recombinant gp120 preparation, media (Fig. 2B) and B6 1 SJL strains (data not shown) showed
normal corticosterone levels.containing 3 or 10 nM gp120, supplemented with 0.1 mM
PMSF, 1 mg/ml leupeptin, 0.2 mg/ml aprotinin, and 1.25% We next examined whether the elevation of plasma
corticosterone levels in young gp120 transgenic micenonfat dry milk, were preincubated either with a nitrocel-
lulose membrane spotted with 100 ng recombinant hu- depended on the level of cerebral gp120 expression.
Homozygous transgenic mice showed higher levels ofman T-cell soluble CD4 (Agmed) or with a control nitro-
cellulose blot without CD4 overnight at 47 before addition cerebral transgene expression (Fig. 1C) and higher
plasma corticosterone levels than heterozygousto the slices. Gp120 avidly binds to CD4 (McKeating et
al., 1992). transgenic mice (Fig. 1B). Transgenic mice of either the
Balb/cByJ or B6 1 SJL background showed similar levelsNG-methyl-L-arginine (LNMA), KCl, and CoCl2 were
from Sigma (St. Louis, MO). All solutions were prepared of transgene expression in the hypothalamus (Fig. 1D).
Gp120 mRNA expression was also detected in the amyg-immediately before use. Memantine was a gift from Dr.
James Larrick (Palo Alto Institute of Molecular Medicine, dala and in the pituitary (not shown).
To ensure that increased plasma corticosterone levelsPalo Alto, CA).
were the result of gp120 expression and not of a line-
specific insertional mutation, plasma corticosterone lev-AVP radioimmunoassay (RIA)
els were measured in heterozygous 9-week-old B61 SJL
mice from another transgenic line, the moderate ex-The concentration of AVP in the hypothalamic slice
media was measured by RIA according to the Skowsky pressor line 10 (Toggas et al., 1994). Levels in these mice
(132 //0 38 ng/ml, n  5) were also significantly highermethod (1974), modified by Weitzman et al. (1978), using
a specific rabbit polyclonal antibody (gift from Dr. A. Bur- than those in nontransgenic littermate controls (35 //0
11 ng/ml, n  4; P  0.05), but lower than those foundlet, Bordeaux, France) and synthetic vasopressin (gift
from Dr. P. Plotsky, Atlanta), as reported previously in mice from line 2 (Fig. 1B).
To exclude the possibility that the increased cortico-(Raber et al., 1994). 125I-AVP was obtained from Amer-
sham (Arlington Heights, IL). Pretitered goat anti-rabbit sterone levels might be caused by effects related to the
regulatory sequences incorporated into the GFAP–serum and normal rabbit serum were from Peninsula
Laboratories, Inc. (Belmont, CA). Standards were mea- gp120 fusion gene, plasma corticosterone levels were
measured in 6-week-old GFAP-TGF-b1 transgenic mice,sured in triplicate, and superfusate samples in duplicate.
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FIG. 1. (A, B) Basal plasma corticosterone levels in gp120 transgenic mice and controls. (A) //0 indicates heterozygous gp120 transgenic Balb/
cByJ mice, 0/0 nontransgenic littermates (n  4–8 mice per group). (B) 0/0 represents nontransgenic controls, 0// heterozygous, and ///
homozygous gp120 transgenic B6 1 SJL mice (n  4–7 mice/group). (C, D) Gp120 mRNA expression in hemibrains (C) and hypothalami (D) of
transgenic mice. Hypothalami were dissected as described under Materials and Methods. Analysis of gp120 mRNA levels in CNS tissues of
nontransgenic (0/0), heterozygous (//0), and homozygous (///) transgenic mice by RNase protection assay was performed as described previously
(Wyss-Coray et al., 1996). Gp120 and actin mRNA levels were determined by RPA using antisense riboprobes for gp120 and murine b-actin,
respectively. The actin signal was used as a control for RNA content/loading. U, undigested radiolabeled probes (no mRNA or RNase added). The
other lanes contained the same riboprobes plus brain RNA samples digested with RNase. Note the prominent increase in plasma corticosterone
levels in gp120 transgenic mice (A, B), the dependence of plasma corticosterone levels on the level of central gp120 transgene expression (B, C),
the strain differences in the magnitude of gp120-induced corticosterone elevations (A, B), and the similar levels of transgene expression in different
strains of gp120 transgenic mice (D).
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FIG. 2. Basal and restraint stress-induced plasma corticosterone levels in 11-week-old (A) and 6-month-old (B) heterozygous gp120 transgenic
Balb/cByJ mice. The mice were anesthetized and tail bled to determine basal levels. Following recovery from anesthesia they were placed in a
restrainer for 15 min, followed by anesthesia and rebleeding. n  4–6 mice/group. **P  0.01 non-Tg restraint vs non-Tg basal and Tg restraint
vs Tg basal; 0P  0.01 Tg vs non-Tg (basal); *P  0.05 Tg vs non-Tg (restraint stress).
which express TGF-b1 from the same GFAP cassette. tors from hypothalamic slices. To assess the general
properties and responsivity of these preparations, hypo-Corticosterone levels in these mice were not significantly
different from those in nontransgenic littermate controls thalamic slices were first stimulated with KCl, which has
(GFAP-TGF-b1 transgenic: 35.69 //0 1.01 ng/ml; non- been shown to effectively induce the release of AVP and
transgenic: 33.44 //0 12.55 ng/ml). CRF from rat hypothalamus (Raber et al., 1994, 1995).
To screen for potential alterations in the dynamic regu- Basal release stabilized after 90 min (Fig. 4A). Therefore,
lation of the HPA axis, we assessed the effect of restraint the 100-min time interval was chosen as the first basal
stress on plasma corticosterone levels. In 11-week-old period in all subsequent experiments. Superfusion with
gp120 transgenic mice, the high basal plasma corticoste- KCl significantly induced AVP release (Fig. 4A). To deter-
rone levels of 428 //0 30 ng/ml were increased further mine whether the KCl-induced AVP release was calcium-
to 825 //0 51 ng/ml, a level significantly higher than that dependent, hypothalamic slices were superfused with
achieved in nontransgenic mice after 15 min of restraint KCl in the presence of CoCl2 , a nonspecific blocker of
stress (Fig. 2A). In contrast, restraint stress-induced calcium channels (Cooper et al., 1991). In the presence
plasma corticosterone levels in 6-month-old transgenic of CoCl2 , the AVP-releasing effect of KCl was completely
mice were similar to those seen in nontransgenic con- blocked (Fig. 4B).
trols (Fig. 2B). To determine the effects of gp120 on hypothalamic
function, slices were superfused with recombinant gp120
Gp120 transgenic mice exhibit increased plasma (10 pM, 3 nM, 10 nM) between 115 and 190 min. As
ACTH levels and pituitary ACTH content shown in Fig. 4C, superfusion with 3 nM gp120 signifi-
cantly increased AVP release after 15 min exposure, an
To determine whether the elevated plasma corticoste-
effect which persisted after the second and third 15-min
rone levels in young gp120 transgenic mice reflect a
collection periods. At lower concentrations, this gp120
central disturbance, plasma ACTH levels and pituitary
effect was less pronounced and more transient (Fig. 4C).ACTH content were analyzed as detailed under Materials
In contrast to AVP, CRF release was not affected byand Methods. At 7 weeks of age, basal plasma ACTH
incubation with 3 nM gp120; however, it was increasedlevels were significantly higher in gp120 transgenic mice
following incubation with 10 nM gp120 (73–232% overthan in their nontransgenic littermates (Fig. 3A). This was
basal after the third gp120 incubation period).paralleled by a significant increase in pituitary ACTH con-
To ensure that the effect of gp120 on AVP release wastent (Fig. 3B). In contrast, basal plasma ACTH levels in
due to gp120 and not to an impurity in the recombinant6-month-old transgenic mice were similar to those seen
gp120 preparation, medium containing either 3 nM or 10in nontransgenic controls (data not shown).
nM gp120 was preabsorbed with human CD4 as de-
scribed under Materials and Methods and subsequentlyGp120 enhances the release of ACTH secretagogues
used to stimulate hypothalamic slices. Preabsorption offrom the hypothalamus
a 3 nM gp120-containing solution with CD4 completely
blocked the gp120-induced AVP release (data notCentral activation of the HPA axis can be mediated by
shown). Preabsorption of the 10 nM gp120 solution withthe ACTH secretagogues AVP and CRF. Therefore, we
studied the effects of gp120 on the release of these fac- human CD4 prevented elevations in AVP release after
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FIG. 3. Basal plasma ACTH levels (A) and pituitary ACTH content (B) in 7-week-old heterozygous gp120 transgenic Balb/cByJ mice. The pituitary
ACTH content was determined as described under Materials and Methods. (A) n  8–10 mice/group. (B) n  3–6 mice/group.
the first superfusion period and strongly inhibited the toxicity in cell culture (Dawson et al., 1993). To investigate
whether the gp120-dependent release of AVP might alsoevoked AVP release after the second and third stimula-
tion periods (Fig. 4D). In contrast, medium containing 10 involve NOS activity, the gp120-stimulated AVP release
was assessed in the presence of NG-methyl-L-argininenM gp120 that was incubated similarly, but in the ab-
sence of human CD4, resulted in a prominent increase (LNMA) (100 mM), a competitive inhibitor of NOS. NOS
inhibition with 100 mM LNMA significantly inhibited thein AVP release after 15 min of exposure, with further
increases observed in the second and third 15-min peri- induction of hypothalamic AVP release by 3 nM gp120
(Fig. 5C).ods (Fig. 4C).
Cobalt chloride, NG-methyl-L-arginine (LNMA) and Gp120/SOD bigenic mice do not show elevated
memantine antagonize the gp120-induced AVP plasma corticosterone levels
release from the hypothalamus
The role of NOS in the action of gp120 could be via
To study the calcium dependency of the gp120-evoked free radical generation and involve reaction of NO with
AVP release, hypothalamic slices were incubated with superoxide anions to form toxic peroxynitrite and its
the calcium channel blocker cobalt chloride (CoCl2 , 10 breakdown products (Lipton et al., 1993; Pietraforte et
mM) during a 15-min basal period and a gp120 stimula- al., 1994; Troy et al., 1996; Xia et al., 1996). In vivo evi-
tion period (between 115 and 190 min). In the presence dence for a role of free radicals in induction of hormonal
of CoCl2 , the 3 nM gp120 induction of AVP release was alterations was sought using crosses of heterozygous
completely blocked (Fig. 5A). gp120 singly transgenic mice with heterozygous singly
Gp120 appears to induce aberrant NMDA receptor ac- transgenic mice expressing the wild-type form of human
tivation, because NMDA antagonists such as 1-amino- superoxide dismutase (SOD) within the CNS (Przedbor-
3,5-dimethyladamantane hydrochloride (memantine) can ski et al., 1992). While plasma corticosterone levels were
inhibit its neurotoxic effects both in vitro and in vivo (Daw- significantly elevated in gp120 singly transgenic offspring
son et al., 1993; Lipton, 1994; Toggas et al., 1996a). We derived from the above cross, levels in gp120/SOD bi-
wanted to determine whether NMDA receptor activation genic littermates were not significantly different from
may also be involved in the gp120 induction of AVP re- those found in nontransgenic controls or SOD singly
lease. Therefore, hypothalamic slices were incubated transgenic mice (Fig. 6).
with gp120 in the presence or absence of memantine
(10 or 100 mM). The inhibitor was present during a 15- DISCUSSION
min basal and a gp120 stimulation period (between 115
and 190 min). Memantine clearly antagonized the gp120- Because HIV-infected humans frequently show alter-
ations of the HPA axis that have the potential to contrib-induced AVP release (Fig. 5B). At 100 mM, memantine
completely inhibited the gp120-induced AVP release in ute to the progression of both AIDS and CNS damage,
it is important to identify the factors that may cause suchthe first stimulation period. Gp120 also failed to induce
significant increases in AVP release in the presence of alterations and to analyze their mode of action. The cur-
rent study demonstrates that cerebral expression of aeither 10 or 100 mM memantine during the two subse-
quent stimulation periods. fusion gene encoding soluble, secretable gp120 in
transgenic mice results in significant elevations inBy elevating intracellular Ca2/ levels, NMDA receptor
stimulation can activate constitutive nitric oxide synthase plasma corticosterone levels, which is prevented in mice
bigenic for human SOD and gp120 (Fig. 7). It further pres-(NOS). Notably, NOS inhibitors can prevent gp120 neuro-
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FIG. 4. AVP release from mouse hypothalamus in vitro. Hypothalamic slices isolated from nontransgenic Balb/cByJ mice were prepared and
superfusate samples collected every 15 min for assaying AVP release as described under Materials and Methods. (A) Time course of basal and
KCl (60 mM)-induced AVP release. After 15 min, samples were collected during consecutive 15-min superfusion periods for a total of 120 min.
Between 105 and 120 min, superfusion was carried out in the presence of 60 mM KCl. Note that basal AVP release is stabilized after 90 min.
Results are expressed as picogram of AVP released per sliced hypothalamus during 15 min. n  8 mice. (B) Calcium dependency of the KCl-
induced AVP release. After 100 min of preperfusion, two samples were collected for a period of 30 min. Between 115 and 130 min, superfusion
was carried out in the presence of 60 mM KCl. Cobalt chloride (10 mM) either was or was not present during the basal and KCl stimulation period
(between 100 and 130 min). n  4–8 mice/condition. Note that the KCl-induced AVP release was calcium dependent, since it was completely
abrogated in the presence of cobalt chloride. (C) Effect of gp120 on basal AVP release. After 100 min preperfusion, a baseline sample (b) was
collected for a period of 15 min (Cooper et al., 1991). Superfusion was then carried out with medium containing 10 pM or 3 nM gp120 during six
subsequent periods (between 115 and 205 min). n  8–13 mice/condition. **P  0.01 vs basal; *P  0.05 vs basal. Note the significant increase
in AVP release in response to 3 nM gp120 which persisted throughout the second and third collection periods. AVP release by 10 pM gp120 was
less pronounced and more transient. (D) Effect of human CD4 or mock-preabsorption on gp120-induced AVP release. After 100 min of preperfusion,
a baseline sample was collected for a period of 15 min (b). Superfusion was carried out during six subsequent periods (between 115 and 205 min)
using media containing 10 nM gp120 that had been preincubated in the presence or absence of human CD4. n  4 mice. **P  0.01 vs basal; *P
 0.05 vs basal; #P  0.05 vs basal and period 1; 0P  0.05 interaction (mock vs CD4 preabsorbed). Note that CD4 preabsorption of media
containing 10 nM gp120 prevented statistically significant elevations in AVP release after the first incubation period and strongly inhibited the
evoked AVP release after the second and third stimulation periods. Preabsorption of media containing 3 nM gp120 with CD4 completely blocked
the gp120-induced AVP release (data not shown).
ents evidence that these hormonal alterations are de- levels of cerebral gp120 transgene expression compared
to heterozygous transgenic mice, also had higher plasmarived from central activation of the HPA axis that is cal-
cium-dependent and involves NMDA receptor stimula- corticosterone levels. Furthermore, the plasma cortico-
sterone levels in heterozygous gp120 mice were lowertion as well as NOS activity.
The dependence of the hormonal alterations observed in the moderate expressor B61 SJL line 10, as compared
to the higher expressor line 2.in gp120 transgenic mice on CNS transgene expression
levels suggests a causal relationship between gp120 and Although it has been impossible to unequivocally iden-
tify gp120 protein within the CNS of gp120 transgenicthe elevation of plasma corticosterone levels: homozy-
gous B6 1 SJL transgenic mice, which showed higher mice using conventional immunohistochemical detection
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FIG. 5. Effect of cobalt chloride (A), memantine (B), and NG-methyl-L-arginine (LNMA) (C) on gp120-induced AVP release from the hypothalamus.
After 100 min of preperfusion, samples were collected during six consecutive 15-min superfusion periods for a period of 90 min. Between 100 and
190 min, superfusion was carried out in the presence of cobalt chloride (10 mM), memantine (10 or 100 mM), or LNMA (100 mM). Gp120 (3 nM)
was present between 115 and 190 min. n  4–8 mice/condition; b, baseline levels. **P  0.01 vs basal; *P  0.05 vs basal. Gp-120-induced AVP
release was blocked by inhibiting calcium channels with cobalt chloride (A). The gp120-induced increase in AVP release over baseline levels was
also prevented by memantine during the first three (100 mM) or the second and third (10 mM) gp120 superfusion periods (B) and by LNMA during
the first three gp120 superfusion periods (C).
methods, gp120 transgenic mice immunized with recom- strain differences have also been reported in rats (Stern-
berg et al., 1989) where they are paralleled by strainbinant gp120 generated an immune response to gp120
and showed prominent CNS infiltrates which were not differences in the degree of adrenal steroid receptor acti-
vation in neural and immune tissues following stress andseen in nontransgenic mice immunized with the same
protein or in gp120 transgenic mice immunized with b- in the content of corticosteroid-binding globulin (CBG) in
plasma, pituitary, and immune tissues (Dhabhar et al.,galactosidase (Toggas and Mucke, 1996). This immune
cell-mediated response strongly supports CNS gp120 ex- 1995). The basal and restraint stress induced plasma
corticosterone levels were elevated only in young gp120pression in the gp120 transgenic mice. However, since
HIV-1 mRNAs can activate interferon-inducible enzymes mice but not in 6-month-old animals. The normal re-
sponse to restraint stress in the older mice indicates that(Maitra et al., 1994), it cannot be excluded that gp120
mRNA may contribute to the CNS alterations found in the normal basal levels were not due to an adaptation
of the HPA axis. It is conceivable that the developingthis model as well as to CNS abnormalities seen in pa-
tients with AIDS. HPA axis has an increased susceptibility to gp120. How-
ever, the reasons for such a possible differential suscep-The observation that plasma corticosterone levels in
heterozygous transgenic Balb/cByJ mice were about tibility of young versus old mice remain unclear.
Usually, elevated plasma corticosterone levels inhibittwice as high as those in heterozygous transgenic B6
1 SJL mice and comparable to those in homozygous ACTH synthesis in and release from the pituitary. In con-
trast, gp120 transgenic mice with increased plasma corti-transgenic B6 1 SJL mice (Figs. 1A and 1B) could be
due to strain differences in HPA axis responsivity. Such costerone levels exhibited elevated plasma ACTH levels
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coln and Wu, 1991; Reyes et al., 1990; Farrah et al., 1991;
Jezova et al., 1991). Direct administration of glutamate
into the paraventricular nucleus (PVN) stimulates ACTH
release, suggesting a hypothalamic site of action for ex-
citatory amino acids stimulation of the HPA axis. Notably,
NMDA receptor agonists have been reported to directly
stimulate the release of AVP but not of CRF from hypotha-
lamic explants (Costa et al., 1992; Patchev et al., 1994).
These data are consistent with the current study which
indicates that gp120 induces AVP release via NMDA re-
ceptor activation, while having a significantly lesser ef-
fect on CRF release. However, since our studies were
performed using hypothalamic explants, we cannot ex-
clude the possibility that gp120 could induce activation of
FIG. 6. Basal plasma corticosterone levels in 5.5- to 10-week-old
CRF via extrahypothalamic afferents. Interestingly, gp120gp120/SOD bigenic mice. Plasma corticosterone was measured in
potentiates NMDA-evoked noradrenaline release fromgp120/SOD bigenic mice (n  7), SOD singly transgenic (n  6), gp120
singly transgenic mice (n  5), and nontransgenic littermate controls hippocampal and cortical nerve endings, but this potenti-
(n  11) (all B6 1 SJL). Differences among non-Tg, SOD Tg, and gp120/ ation is not sensitive to NOS inhibitors and, in contrast
SOD bigenic mice were not statistically significant. However, levels of to the gp120-evoked AVP release from the hypothalamus,
these three groups were significantly different from those found in
gp120 alone does not evoke noradrenaline release (Pitta-gp120 Tg mice.
luga and Raiteri, 1994). This suggests that gp120 may
affect neurotransmitter release in a brain region and neu-
rotransmitter-specific fashion.and pituitary ACTH content (Figs. 3A and 3B). It has pre-
viously been shown that AVP functions as an effective Gp120 neurotoxicity in primary cortical cultures could
be attenuated by addition of the free radical scavengerACTH secretagogue: an important component of ACTH
activation observed during exposure to strong systemic SOD and almost completely blocked by addition of SOD
in combination with a NOS inhibitor (Dawson and Daw-stressors depends on AVP release (Carlsson and Gann,
1984; Giuffre et al., 1988), and AVP has been implicated son, 1994). Cortical cultures from neuronal NOS-defi-
cient mice are resistant to NMDA and hypoxic neurotox-in the maintenance of the HPA axis activity after repeated
activation (Scaccianoce et al., 1991; Hauger et al., 1988; icity, supporting a role for NOS in mediating neuronal
damage (Dawson et al., 1996). Analysis of CNS pathol-Hashimoto et al., 1988). The current experiments in which
nontransgenic hypothalamic slices were exposed to re- ogy in gp120/SOD bigenic mice revealed a neuroprotec-
tive potential of SOD against gp120-induced neuronalcombinant gp120 demonstrate that gp120 induces hypo-
thalamic AVP release in a calcium-dependent manner damage, as reflected by rescue from drop-out of synap-
tophysin-immunoreactive presynaptic terminals (Tog-(Fig. 4), indicating a role for AVP in gp120-induced HPA
axis activation. Because low levels of gp120 transgene gas et al., 1996b). Since it has been shown that NOS
can generate superoxide anions (Pou et al., 1992; Xiaexpression were detected by RPA in the pituitary of
gp120 transgenic mice (data not shown), we cannot ex- et al., 1996), the prevention of HPA axis activation found
in SOD/gp120 bigenic mice might relate to SOD-medi-clude the possibility that in vivo gp120 might also en-
hance pituitary ACTH synthesis and/or release via a ated elimination of superoxides (Mollace et al., 1994;
Dawson et al., 1993; Pietraforte et al., 1994; Xia et al.,more direct mechanism.
Although the exact mechanism by which gp120 modu- 1996) generated by NOS.
The gp120-associated derangements of the HPA axislates AVP release from the hypothalamus remains to be
determined, the prominent effects of memantine and described in this study may have relevance to the sce-
nario encountered in HIV-infected humans, who fre-LNMA demonstrated here (Fig. 5) strongly suggest that
NMDA receptor stimulation and NOS activity play an im- quently show abnormal cortisol levels (reviewed in Vago
et al., 1994). In addition to gp120, cytokines releasedportant role in this process. Glutamate has been strongly
implicated in HIV-1-associated neurotoxicity (see Lipton, from activated immune cells into the circulation may also
contribute to an activation of the HPA axis in AIDS pa-1994, for review). It also appears to be involved in neuro-
endocrine regulation (van den Pol et al., 1990) and to be tients (Rivier, 1995). Notably, glucocorticoids can induce
neuropathological alterations (Starkman et al., 1992; Dethe predominant excitatory transmitter for stimulation of
hypothalamic cells producing AVP or oxytocin (Meeker Leon et al., 1989; Landfield, 1987; Sapolsky, 1992), and
in pediatric AIDS patients evidence for hippocampal atro-et al., 1993). The potent effect of excitatory amino acids
on the release of ACTH and, consequently, glucocorti- phy or generalized atrophy has been identified by com-
puted tomography most frequently in children with ele-coids seems to be mediated mainly by NMDA receptor
activation (Gay and Plant, 1987; Iyengar et al., 1990; Lin- vated cortisol levels (Oberfield et al., 1994). Glucocorti-
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FIG. 7. Schematic outline of HIV gp120-induced HPA axis activation and potential pathogenetic consequences. This study shows for the first
time that the transgene-mediated CNS expression of HIV-1 gp120 can induce HPA axis activation in vivo resulting in hormonal alterations similar
to those found in a proportion of AIDS patients. In addition, recombinant gp120 was shown to elicit the release of the ACTH secretagogue AVP
from the hypothalamus. Increased hypothalamic AVP release could promote ACTH release from the anterior pituitary, which would stimulate the
adrenal gland and thereby lead to increased corticosterone levels in the systemic circulation. The current study also identified potential strategies
to interfere with HIV-associated HPA axis alterations: gp120-induced hypothalamic AVP release was strongly inhibited by NMDA receptor blockers
as well as by inhibitors of NOS. Furthermore, bigenic gp120 mice overexpressing wild-type human SOD in their CNS showed no HPA axis activation,
providing evidence that reduction in superoxide levels might help prevent or ameliorate HIV-induced neuroendocrine abnormalities.
coids also have the potential to enhance HIV-1 inhibitory protein, which traps activated NF-kB (Schein-
man et al., 1995; Auphan et al., 1995).replication via the high affinity mineralocorticoid (MR or
In conclusion, the current study indicates that the sig-type I) receptor, which is a target of the HIV-1 vpr gene
nificant elevations in plasma corticosterone levels foundproduct (Refaeli et al., 1995). These hormones could con-
in young gp120 transgenic mice are due to central activa-tribute to the progression of AIDS and AIDS dementia
tion of the HPA axis. The results obtained from exposurecomplex through their effects on the immune system
of hypothalamic slice preparations to recombinant gp120(Wilckens, 1995) and the CNS. In addition, glucocorti-
suggest that gp120 increases ACTH release from thecoids have been shown to inhibit glucose transport into
pituitary by stimulating AVP release from the hypothala-hippocampal neurons, making these neurons more sen-
mus. Using appropriate inhibitors, the latter process wassitive to kainic acid and metabolic toxins (Sapolsky,
shown to be calcium-dependent and to involve stimula-1992). Increased neuronal vulnerability could also result
tion of NMDA receptors and NOS activity. It is conceiv-from a glucocorticoid-mediated reduction of brain-de-
able that similar pathogenetic pathways may contributerived neurotrophic factor mRNA (Smith et al., 1995; Segal
to endocrinological and neurological abnormalities foundet al., 1995). Furthermore, glucocorticoid response ele-
in HIV-1-infected humans.ments are found in diverse genes, including those encod-
ing cytokines and other immune response mediators (for
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